English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish
Receive the latest event information about key speakers, sponsorship opportunities and exhibiting.
How much does your state save? 🇺🇸 In 2019, generic medicines saved #Kentucky $6.5B, and $313B for the U.S. health care system overall. Use the interactive map to see how much your state saved: https://accessiblemeds.org/2020-Access-Savings-Report#map #GRxBiosimsSavingsReport #generics #biosimilars
Concerned about #biosimilar uptake? Bipartisan payment proposals could increase patient access and savings. View recommendations by AAM’s VP Policy Craig Burton. https://biosimilarscouncil.org/resource/savings-biosimilars-adoption/
@AccessibleMeds #MedicarePartB #patientaccess
We appreciate the leadership of @SenatorCollins on the Making Pharmaceutical Markets More Competitive Act. @US_FDA approved the first generic for Daraprim in 2020. https://www.help.senate.gov/hearings/why-does-the-us-pay-the-highest-prices-in-the-world-for-prescription-drugs
#drugprices #generics
Want lower #drug costs? Try increase #generic competition. Here is @DerekHosford's blog:
Want Lower Drug Costs? Increase Generic Competition - The American Consumer Institute
The list price of prescription drugs has already risen this year an average of 4.5%, with most of the increases coming from drugs that do not have a g...
www.theamericanconsumer.org
Today is #WorldHealthDay: Its celebration aims to draw attention to specific health themes. In accordance with our claim of #caringforlife, we want to help raising awareness for these priority areas.
#freseniuskabi #caringforlife
Association for Accessible Medicines
601 New Jersey Ave NW, Suite 850
Washington, DC 20001
P: 202.249.7100
E: info@accessiblemeds.org
STAY CONNECTED
Association for Accessible Medicines
Biosimilars Council
Whether you are an AAM member, general attendee, or exhibitor, come meet the leaders and decision-makers who are determining the future of generics and biosimilars.
Whether you are an AAM member, general attendee, or exhibitor, come meet the leaders and decision-makers who are determining the future of generics and biosimilars.
